This finding further supports the potential clinical utility of PDK1 as a biomarker for osteosarcoma.Although our study focused on the effects of PDK1 silencing in osteosarcoma, multiple studies have shown that PDK1 overexpression enhances tumor aggressiveness. Here, PDK1 is linked to osteosarcoma.